Citi: Eli Lilly third-quarter earnings preview: Citi bets on growth from two drugs as Medicare coverage and a new oral treatment open avenues for expansion
Citi expects combined third-quarter sales of Mounjaro and Zepbound to reach 15.6 billion dollars, with both above the Visible Alpha consensus; new Medicare patients, the launch of an oral drug and restored channel access are key sales trends to watch.